Synergistic antiviral activity against drug-resistant HIV-1 by naturally occurring dipeptide and A single-stranded oligonucleotide

Rafael Ceña-Diez; Anna-Lena Spetz; Anders Sönnerborg

doi:10.1016/j.drup.2023.100955

Synergistic antiviral activity against drug-resistant HIV-1 by naturally occurring dipeptide and A single-stranded oligonucleotide

Drug Resist Updat. 2023 May:68:100955. doi: 10.1016/j.drup.2023.100955. Epub 2023 Mar 4.

Authors

Rafael Ceña-Diez¹, Anna-Lena Spetz², Anders Sönnerborg³

Affiliations

¹ Division of Infectious Diseases/ANA Futura, Department of Medicine Huddinge, Karolinska Institutet, Alfred Nobels Allé 8, 141 52 Huddinge, Sweden. Electronic address: rafael.cena.diez@ki.se.
² Department of Molecular Biosciences, Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.
³ Division of Infectious Diseases/ANA Futura, Department of Medicine Huddinge, Karolinska Institutet, Alfred Nobels Allé 8, 141 52 Huddinge, Sweden; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, 141 52 Huddinge, Sweden.

PMID: 36878096
DOI: 10.1016/j.drup.2023.100955

Abstract

The novel dipeptide WG-am and single-stranded oligonucleotide combination (WG-am:ssON) showed synergistic antiviral activity against HIV-1 integrase-, protease- or reverse transcriptase drug resistant isolates, with over 95% reduction. The highest selectivity indexes were for integrase resistant isolates. WG-am:ssON can be a future option for treatment of HIV drug-resistant strains.

Keywords: Combination; Dipeptide; Drug resistance; HIV; INSTI; SsON; Synergy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use
Drug Resistance, Viral / genetics
HIV Integrase Inhibitors* / pharmacology
HIV Integrase Inhibitors* / therapeutic use
HIV-1* / genetics
Humans
Oligonucleotides / pharmacology

Substances

Antiviral Agents
HIV Integrase Inhibitors
Oligonucleotides